Division of Biostatistics and Epidemiology, Medical University of South Carolina, Charleston, SC 29425-8150, USA.
Clin Trials. 2011 Oct;8(5):601-8. doi: 10.1177/1740774511418848. Epub 2011 Sep 15.
The literature on the design, conduct, and analysis of non-inferiority trials is continuously evolving. Several design issues continue to be researched including the choice of active control, choice of non-inferiority margin, and optimal analytic approaches. To date, there has been relatively little in the literature documenting actual experiences with implementing available methodology for non-inferiority trials.
This article serves as a case study and highlights some of the challenges encountered in the design of a Phase III non-inferiority trial in status epilepticus that is being conducted under a Food and Drug Administration Investigational New Drug Application (IND).
The IND application was put on clinical hold by the Food Drug and Administration due to concerns with the design. Specifically, support for the active control, non-inferiority margin, and overall interpretability of trial results were questioned, and a recommendation was made to consider a superiority design. The authors describe their interactions with the Food Drug and Administration and their application of available methods and approaches to address these concerns.
The investigators' response to the clinical hold provided detailed information to support the conduct of a non-inferiority trial. The study team received Food Drug and Administration approval to initiate the trial in October 2008. The trial enrollment began in June 2009 and is being conducted by roughly 800 paramedic units in over 40 Emergency Medicine Service systems across the United States.
There is still a great deal of methodological research needed to fully understand the application and impact of the non-inferiority trial design.
It is evident that non-inferiority trials have an important place in clinical trial design and analysis. These trials may be the only way and only opportunity to answer certain questions; so, they must be designed and conducted with rigor. This case study is an attempt to share our experiences in implementation.
关于非劣效性试验的设计、实施和分析的文献在不断发展。包括选择活性对照、选择非劣效性边界和最佳分析方法在内的几个设计问题仍在继续研究。迄今为止,文献中几乎没有记录实际应用非劣效性试验现有方法的经验。
本文作为一个案例研究,重点介绍了在癫痫持续状态的 III 期非劣效性试验设计中遇到的一些挑战,该试验正在根据食品和药物管理局的新药研究申请(IND)进行。
由于对设计的担忧,食品和药物管理局对 IND 申请进行了临床搁置。具体而言,对活性对照、非劣效性边界和试验结果的整体可解释性提出了质疑,并建议考虑进行优效性设计。作者描述了他们与食品和药物管理局的互动以及他们应用现有方法和方法来解决这些问题。
调查人员对临床搁置的回应提供了详细信息,以支持进行非劣效性试验。研究小组于 2008 年 10 月获得食品和药物管理局批准开始试验。试验招募于 2009 年 6 月开始,由美国 40 多个紧急医疗服务系统的大约 800 个护理人员单位进行。
要充分了解非劣效性试验设计的应用和影响,仍需要进行大量的方法学研究。
非劣效性试验显然在临床试验设计和分析中占有重要地位。这些试验可能是回答某些问题的唯一途径和唯一机会;因此,它们必须严格设计和进行。本案例研究旨在分享我们在实施方面的经验。